The global biosimilar monoclonal antibodies market is expected to grow at a CAGR of 9.6% in the second half of the forecast period. The market is expected to grow at a CAGR of 23.8% from 2015-2027. The market is estimated at $4.2bn in 2020 and $7.9bn in 2027.

How this report will benefit you
  • Read on to discover how you can exploit the future business opportunities emerging in this sector.
  • In this brand new 204-page report you will receive 72 tables and 72 figures– all unavailable elsewhere.
  • The 204-page report provides clear detailed insight into the global biosimilar monoclonal antibodies market. Discover the key drivers and challenges affecting the market.
  • By ordering and reading our brand new report today you stay better informed and ready to act.
Report Scope

Along with revenue prediction for the overall world market for biosimilar monoclonal antibodies, our investigation shows forecasts to 2027 for the market segmented by compound:
  • Infliximab
  • Rituximab
  • Abciximab
  • Trastuzumab
  • Adalimumab
  • Bevacizumab
This report also shows revenue to 2027 for individual biosimilar mAb products in the market:
  • Remsima/Inflectra
  • Infimab
  • Reditux
  • BI695500
  • CT-P10
  • BI695501
  • FKB327
  • FKB238
  • Mabtas
  • AcellBia
  • Maball
  • Clotinab
  • Abcixirel
  • BCD-022
  • BCD-021
  • Herzuma
  • CANMAB/Hertraz
Our analyses show individual revenue forecasts to 2027 for these regional and national markets:
  • The US Biosimilar mAb Market
  • Japanese Biosimilar mAb Market
  • EU5 Biosimilar mAb Markets
  • BRIC and South Korea Biosimilar mAb Markets
  • Rest of the World Biosimilar mAb Market
Global Biosimilar Monoclonal Antibodies Forecast 2020-2030
  • This report profiles 10 leading companies either with biosimilar mAbs already on the market or in the pipeline
  • Our study discusses strengths, weaknesses, opportunities and threats affecting the biosimilar monoclonal antibodies market